Discover
SAVA
Cassava Sciences Inc
2.38
2 x 2.34
2 x 2.41
bid
ask
+
0.26
12.26%
2 @ 04:00 PM
2.34 -0.04 (1.52%)
Ytd 20.20%
1y 36.00%
2.19
day range
2.49
1.19
52 week range
4.64
Open 2.19 Prev Close 2.12 Low 2.19 High 2.49 Mkt Cap 115.95M
Vol 2.06M Avg Vol 5.19M EPS -1.38 P/E N/A Forward P/E -1.36
Beta -0.58 Short Ratio 1.95 Inst. Own 29.93% Dividend N/A Div Yield N/A
Ex Div Date 12-13 Earning 05-07 50-d Avg 17.99 200-d Avg 21.09 1yr Est 116.00
Earning
Date For Estimate Reported Surprise surprise %
2024-11-07 2024-09 -1.37 -0.58 0.79 57.66%
2024-08-08 2024-06 -0.44 -1.28 -0.84 -190.91%
2024-05-10 2024-03 -0.51 -1.41 -0.9 -176.47%
2024-02-28 2023-12 -0.4 -0.5 -0.1 -25.00%
2023-11-07 2023-09 -0.9 -0.61 0.29 32.22%
2023-08-03 2023-06 -0.58 -0.63 -0.05 -8.62%
Upgrade / Downgrade
Date Firm Action From To
2024-11-26 HC Wainwright & Co. Downgrade Buy Neutral
2024-11-08 HC Wainwright & Co. Upgrade Buy Buy
2024-10-08 HC Wainwright & Co. Upgrade Neutral Buy
2024-08-13 HC Wainwright & Co. Upgrade Neutral
2024-08-08 Rodman & Renshaw Upgrade Buy Buy
2024-07-19 HC Wainwright & Co. Upgrade Neutral
Profile
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Insider Holder
Date Name Relation Quantity Description
2023-05-23 BARBIER REMI Chief Executive Officer 0.00 Conversion of Exercise of derivative security
2024-04-22 BARRY RICHARD J Director 0.00 Conversion of Exercise of derivative security
2023-04-30 GUSSIN ROBERT Z Director 10.62K Conversion of Exercise of derivative security
2024-11-28 KUPIEC JAMES WILLIAM Officer 0.00 Sale
2023-03-06 O DONNELL MICHAEL J Director 6.87K Conversion of Exercise of derivative security
2024-05-15 ROBERTSON SANFORD R Director 1.14M Stock Gift
Institution Ownership
Report Date Organization Position Value Percentage
2024-09-29 Blackrock Inc. 3.26M 7.86M 6.78%
2024-09-29 Vanguard Group Inc 2.52M 6.08M 5.24%
2024-09-29 State Street Corporation 1.16M 2.80M 2.42%
2024-09-29 Geode Capital Management, LLC 1.01M 2.43M 2.10%
2024-09-29 Gallacher Capital Management LLC 580.04K 1.40M 1.21%
2024-09-29 Morgan Stanley 519.54K 1.25M 1.08%
Fund Ownership
Report Date Organization Position Value Percentage
2024-09-29 Vanguard Total Stock Market Index Fund 1.28M 3.08M 2.65%
2024-10-30 iShares Russell 2000 ETF 1.05M 2.52M 2.17%
2024-09-29 Vanguard Extended Market Index Fund 678.63K 1.64M 1.41%
2024-08-30 Fidelity Small Cap Index Fund 415.51K 1.00M 0.86%
2024-10-30 iShares Russell 2000 Growth ETF 362.96K 874.73K 0.75%
2024-10-30 Fidelity Extended Market Index Fund 251.56K 606.26K 0.52%
Dividend
Dividend Date
0.75 2012-12-13
2 2010-12-13
Split
Split Date
1 : 7 2017-05-10